New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback